PMID- 21638933
OWN - NLM
STAT- MEDLINE
DCOM- 20110622
LR  - 20171116
IS  - 1007-8738 (Print)
IS  - 1007-8738 (Linking)
VI  - 27
IP  - 3
DP  - 2011 Mar
TI  - [Multiprobe fluorescence in situ hybridization panel in detection of the common 
      cytogenetic abnormalities of acute myeloid leukemia].
PG  - 324-6
AB  - AIM: To evaluate the value of multiprobe Fluorescence in situ hybridization 
      (FISH) panel in detection of the common cytogenetic abnormalities in acute 
      myeloidleukemia( AML). And to investigate its association with clinical 
      diagnosis, chemotherapy and prognosis. METHODS: Using the multiprobe AML/MDS 
      panel designed to detect upto eight different FISH probes, which was for AML1/ETO 
      transfusion gene, PML-RARalpha transfusion gene, CBFbeta/MYH11 transfusion gene, MLL 
      breakapart, P53 deletion,Del(5q), Del(7q), Del(20q), 40 cases of AML were 
      investigated. The conventional karyotype analysis and the in-formation about the 
      treatment responses were also used for assessing. RESULTS: 22 of the 40 AML cases 
      were found to carry 7 types of cytogenetic abnormalities by multiprobe FISH panel 
      including AML1/ETO transfusion gene, PML-RARa transfusion gene, MLL breakapart, 
      P53 deletion, Del (5q), Del7q and trisomy 8. However conventional karyotype 
      analysis only discovered 11 cases with the corresponding cytogenetic 
      abnormalities, the positive ratio was 57.5% in multiprobe FISH panel higher than 
      that in karyotype analysis (27.50%). Patiens with AML1/ETO or PML-RARa 
      transfusion gene are easily to reach CR in the first induction chemotherapy, 
      while the Del(7q), MLL breakapart, complex cytogenetic abnormalities may indicate 
      poor prognosis. CONCLUSION: Mutiprobe FISH panel is more rapid, accurate and 
      effective for detecting the common cytogenetic abnormalities in AML, compared 
      with the conventional karyotype analysis and common FISH analysis.
FAU - Xu, Lu-lu
AU  - Xu LL
AD  - Department of Hematology, Nanfang Hospital, Southern Medical University, 
      Guangzhou 510515, China.
FAU - Liu, Xiao-li
AU  - Liu XL
FAU - Du, Qing-feng
AU  - Du QF
FAU - Song, Lan-lin
AU  - Song LL
FAU - Cao, Rui
AU  - Cao R
FAU - Wei, Yong-qiang
AU  - Wei YQ
FAU - Xu, Na
AU  - Xu N
FAU - Zhang, Jin-fang
AU  - Zhang JF
LA  - chi
PT  - Journal Article
PL  - China
TA  - Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
JT  - Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular 
      immunology
JID - 101139110
RN  - 0 (AML1-ETO fusion protein, human)
RN  - 0 (CBFbeta-MYH11 fusion protein)
RN  - 0 (Core Binding Factor Alpha 2 Subunit)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (RUNX1 Translocation Partner 1 Protein)
RN  - 0 (promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein)
RN  - 149025-06-9 (Myeloid-Lymphoid Leukemia Protein)
RN  - Chromosome 8, trisomy
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - *Chromosome Aberrations
MH  - *Chromosome Deletion
MH  - Chromosomes, Human, Pair 8/genetics
MH  - Core Binding Factor Alpha 2 Subunit/analysis
MH  - Female
MH  - Genes, p53/genetics
MH  - Humans
MH  - Hybridization, Genetic
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Karyotyping/methods
MH  - Leukemia, Myeloid, Acute/*genetics/*pathology
MH  - Male
MH  - Middle Aged
MH  - Myeloid-Lymphoid Leukemia Protein/*analysis
MH  - Oncogene Proteins, Fusion/*analysis
MH  - RUNX1 Translocation Partner 1 Protein
MH  - Reproducibility of Results
MH  - Substrate Specificity
MH  - Trisomy/genetics
EDAT- 2011/06/07 06:00
MHDA- 2011/06/23 06:00
CRDT- 2011/06/07 06:00
PHST- 2011/06/07 06:00 [entrez]
PHST- 2011/06/07 06:00 [pubmed]
PHST- 2011/06/23 06:00 [medline]
PST - ppublish
SO  - Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2011 Mar;27(3):324-6.